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The growing relevance of cap-independent translation
initiation in cancer-related genes
Abstract
Two main mechanisms for eukaryotic initiation of protein synthesis have been
described – the canonical cap-dependent and the alternative cap-independent.
They mainly differ in their requirement for 7-methylguanosine cap at 5’ end of
mRNA molecules to initiate translation. In cap-independent translation initia-
tion, an element within 5’ untranslated region (5’ UTR) of mRNA, defined in-
ternal ribosome entry site (IRES), recruits 40S ribosomal subunit directly or
close to the start codon without the need for the 5’ cap.
Some cellular mRNAs – including those encoding for a number of growth
factors, oncogenes, receptors, survival proteins, transcription and translation
factors – contain IRES elements within their 5’ UTR what may allow them to
be translated under different physiological or stress conditions (e.g., amino acid
starvation, apoptosis, growth arrest, heat shock, mitosis, radiation) when global
cap-dependent protein synthesis is suppressed. IRES-dependent translation may
escape the control of checkpoints present in cap-dependent regulation causing
improper protein synthesis that can lead to cell apoptosis or disease. A growing
number of cancer-related genes have been reported whose translation initiation
depends on the presence of IRES element in their mRNA. These findings make
the quest for discovering and testing new putative cellular IRESes even more
meaningful. A deeper understanding of the role of IRES-dependent translation
initiation in cancer etiology could ultimately give us a novel targets for cancer
therapy.
REGULATION OF EUKARYOTIC PROTEIN
SYNTHESIS
Protein synthesis is the final step in the flow of genetic information. Inthe process of translation the nucleotide sequence encoded in a mes-
senger RNA (mRNA) molecule is converted through genetic code into a
protein product. This process is divided into three consecutive stages –
initiation, elongation, and termination. It is considered that initiation is the
rate-limiting step and is highly regulated in eukaryotes (1). Translational
control is one aspect of the post-transcriptional regulation of gene expres-
sion and has a significant impact on the cellular proteome composition (2).
Selective translation allows rapid cellular adaptation to changes in physio-
logical conditions without involving new mRNA synthesis and transport
(3). On the other hand, improper protein synthesis can lead to cell apop-
tosis or disease (3, 4). In cancer cells, hyperactivated signaling pathways
influence translation rates supporting the uncontrolled growth and survi-
val. Consistently, several components of translation initiation system have
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oncogenes (5). In cancer, translational alterations can incre-
ase the overall rate of protein synthesis as well as activate the
translation of specific mRNAs for the proteins that promote
cancer progression and metastasis (5).
Generally there are two main mechanisms of euka-
ryotic protein synthesis initiation – the canonical cap-
-dependent and the alternative internal cap-independent
initiation of translation. Each mechanism relies on a
complex interplay involving recognition of mRNA by
specific subset of eukaryotic initiation factors (eIFs) fol-
lowed by recruitment of the ribosome subunits, recog-




The vast majority of eukaryotic mRNAs initiate transla-
tion by a mechanism that require the presence of the 5’-7-
methylguanosine structure (termed 'm7G-cap' or merely
'cap') located at the 5'-end of most mRNAs (Figure 1A). A
large number of helping proteins termed eukaryotic transla-
tion factors (eIFs) mediate these processes. The 5' cap is
recognized by cap-binding complex eIF4F that is composed
of eIF4E (cap-binding protein), eIF4A (an RNA helicase)
and eIF4G (a scaffolding protein). The eIF4G further inte-
racts with eIF3 and the poly(A)-binding protein (PABP)
that is bound to the poly(A)-tail of the mRNA, leading to a
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Figure 1. Similarities and differences between canonical cap-dependent and cap-independent internal initiation of translation in eukaryotes. (A) Cap-dependent
initiation mechanism requires an mRNA molecule with m
7
G-cap on its 5’ end. A large number of proteins termed eukaryotic translation factors (eIFs) participate in
the processes of recognition of the m
7
G-cap operated by cap-binding complex eIF4F (composed of eIF4E, eIF4A and eIF4G), but also in the recruitment of the 43S
pre-initiation complex (composed of 40S ribosomal subunit, eIF2, eIF3 and initiator methionyl-transfer RNA), 5’ to 3’ directional scanning of the 43S complex along
mRNA 5’ untranslated region (5’ UTR), recognition of start codon (AUG) in appropriate context, and joining of the 60S ribosomal subunit with 40S subunit leading
to the 80S ribosome ready to translate an open reading frame (ORF). (B) In cap-independent initiation, the main difference is that an element within mRNA molecule
named internal ribosome entry site (IRES) recruits 40S ribosomal subunit directly or close to the translation start codon without the need for m
7
G-cap and eIF4E.
Molecular mechanisms behind cap-independent initiation depend on the presence of an IRES element and may or may not require canonical eIFs and/or auxiliary
proteins named IRES trans-acting factors (ITAFs).
functional circularization and activation of the mRNA mo-
lecule. Binding of eIF4F leads to the recruitment of 43S
preinitiation complex that is composed of the 40S ribosomal
subunit, eIF2, eIF3 and the initiator methionyl-transfer
RNA (Met-tRNAi). The 43S complex with assistance of
eIF1 and eIF1A scans the mRNA in a 5' to 3' direction until
the first start codon (AUG) within an appropriate sequence
context (GCC[A/G]CCAUGG, termed Kozak consensus
sequence) is found, which leads to the formation of the 48S
initiation complex. At this step eIF1 is released, eIF5 media-
tes the hydrolysis of eIF2-bound GTP and eIF5B mediates
joining of the 60S ribosomal subunit with the 40S subunit
thus assembling a translationally capable 80S ribosome.
This cap-dependent translation initiation mechanism is pre-




Overexpression of several components of translation ini-
tiation machinery was shown to cause or to strongly corre-
late with malignant transformation. The cap-binding pro-
tein eIF4E, the least abundant eIF and hence considered to
be a rate limiting factor for cap-dependent translation, is
found upregulated in the majority of human cancers and its
high expression levels correlate with poor prognosis (8).
Overexpression of eIF4E can also increase the translation of
mRNAs with structured 5' untranslated region (5' UTR)
that are normally translated with less efficiency (9). Intri-
guingly, many transcription factors, growth factors, recep-
tors and tyrosine kinases have suchlike mRNAs (10). Many
characteristics of eIF4E make it a promising target for can-
cer therapy (11).
The other eukaryotic translation initiation factors known
to be dysregulated in human cancers are listed in Table 1.
CAP-INDEPENDENT (INTERNAL)
TRANSLATION INITIATION
Lack of oxygen (hypoxia), starvation and response to
DNA damage-inducing therapy represses cap-dependent
translation and leads to reduced levels of overall protein
synthesis (33). In parallel, inhibition of cap-dependent pro-
tein synthesis allows the subset of mRNAs to be translated in
a cap-independent manner using mRNA elements termed
internal ribosomal entry sites (IRESes) which are predomi-
nantly located in the 5’ UTR (34).
As suggested by the definition, cap-independent initia-
tion does not require the m7G-cap to recruit a ribosome to
the mRNA (Figure 1B). According to this mechanism, mRNA
sequence itself has ability to bind and activate the transla-
tional machinery. There are many different mechanisms by
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TABLE 1
Eukaryotic translation initiation factors (eIFs) dysregulated in various human cancers.
Factor
name










binds ribosomal 40S subunit, eIF1, eIF4G and eIF5; stimulates
binding of eIF2–GTP–Met-tRNAi to 40S subunit; promotes
attachment of 43S complex to mRNA and subsequent
scanning; possesses ribosome dissociation and anti-association
activities that prevent joining of 40S and 60S subunits
eIF3a breast, cervix, esophagus, lung upregulated (14, 15)
eIF3b breast upregulated (14)
eIF3c testis upregulated (16)
eIF3e breast, non-small cell lungcancer downregulated (17)
eIF3f pancreas, breast, ovary downregulated (18)
eIF3h breast, prostate upregulated (19)
eIF4A DEAD-box ATPase and ATP-dependent RNA helicase hepatocellular carcinoma,melanoma upregulated (20, 21)
eIF4E binds to m7G-cap structure of mRNA









GTPase-activating protein, specific for GTP-bound eIF2;
induces hydrolysis of eIF2-bound GTP on recognition of
initiation codon
ovary, pancreas, colorectal
carcinoma upregulated (31, 32)
which IRESes can initiate translation – some of them re-
quire canonical eIFs while the others can engage auxiliary
proteins not normally associated with translation. These
RNA-binding proteins named IRES trans-acting factors
(ITAFs) are thought to help in proper folding of the IRES
region facilitating the the recruitment of the translation
machinery on the mRNA (35).
The cap-independent mechanism was first discovered in
the 5’ UTR of two picornaviruses – encephalomyocarditis
virus and poliovirus (36, 37). Some picornaviruses can inhi-
bit cap-dependent protein synthesis in infected host cells by
virus-encoded proteases that are able to cleave eIF4G and
PABP, the key components of cap-dependent translation
initiation (38). By this mechanism the virus can block host
anti-viral response. The first cellular IRES was found in
mRNA encoding for the immunoglobulin heavy chain-
-binding protein (BiP). It was discovered owing to its per-
sisting activity in poliovirus-infected cells although trans-
lation of majority of host mRNAs was stopped (39).
THEORETICAL AND EXPERIMENTAL
CONSIDERATIONS FOR SEEKING IRESes
IN CELLULAR mRNAs
The ability of an RNA molecule to function as IRES is
entirely encoded in its primary sequence but it is also appa-
rent that higher order secondary and three-dimensional
structures are determinants of IRES activity (40). The mRNAs
with long 5’ UTR (200 to 500 nucleotides), predicted as
heavily structured and with high GC content were tradi-
tionally considered strong candidates for having IRES ele-
ments and at the same time incapable of efficient translation
by canonical cap-dependent ribosome scanning mechanism
(41). Le and Maizel introduced a prediction rule whereby a
Y-shaped double-hairpin structure followed by a small hair-
pin would constitute an IRES RNA motif that can in fact be
found upstream of the start-site codon in a variety of cellular
mRNA (42). Still there is no direct experimental evidence
for IRES functionality of this motif. Other structural ele-
ments that may suggest functional IRESes could be the
presence of polypyrimidine tracts, pseudoknots near the
start codon, or hairpin-loops mimicking those present in the
IRESes of picornavirus, hepatitis C virus (HCV), or the
intergenic region (IGR) of dicistrovirus RNA genomes (43).
Presence of one or more of these elements may provide hints
to select potential cellular IRES for further experimental
validation.
The most widely used experimental approach for testing
the presence of a cellular IRES in a 5’ UTR is based on
bicistronic reporter assays (40, 44, 45). The putative IRES
sequence is cloned into the inter-cistronic region between
two different reporter genes (e.g., Firefly/Renilla luciferase).
Transcription driven from an upstream promoter should
give one bicistronic mRNA transcript. Expression of the up-
stream reporter should occur through cap-dependent mecha-
nism, whereas the downstream reporter should be trans-
lated only if the inserted sequence exhibits IRES activity
thus allowing ribosomes to be recruited to the mRNA in-
ternally (~1kb downstream from m7G-cap). The same dual
reporter vector without inserted fragment ('empty' vector) is
often used as a negative control, while a proven IRES se-
quence is used as a positive control. If activity of the down-
stream reporter is greater for the putative IRES element than
non-IRES control, the candidate RNA is considered as a
potential IRES-containing sequence. In addition, to establish
that differences in reporter activity are due to translational
and not to transcriptional processes, (e.g., that the cloned
sequence can act as a cryptic promoter), the bicistronic
nature of the reporters’ mRNA should be examined by PCR
in the control vectors as well as those containing the inserted
IRES candidate. Reporter assays based on dual-cistronic
DNA constructs can indeed give false positive results owing
to the fact that inserted mRNA acts as a cryptic promoter or
can lead to an alternative splicing event resulting in m7G-
-capped monocistronic mRNA containing just the down-
stream reporter. To avoid these potential ambiguities it is
better to use in vitro transcribed bicistronic mRNA that is
purified and transfected in a cell line for the reporter assay
(40, 45). Testing potential IRESes with monocistronic re-
porter assays requires using vector constructs with m7G-cap
analogs or hairpin-loop structures positioned upstream of
the reporter gene open reading frame that should facilitate
utilization of IRES-dependent internal translation initia-
tion (40).
Since there is no single 'gold-standard' procedure that
can be used to definitely confirm the presence of IRES
within an mRNA molecule, a series of carefully planned and
controlled experiments should be designed to eliminate all
possible alternative explanations.
474 Period biol, Vol 114, No 4, 2012.
P.Ozreti} et al. Cap-independent translation of cancer genes
TABLE 2
Cancer-related genes whose mRNAs are reported to
contain cellular IRES elements.
Protein function Gene symbol References
















DNA damage response SHMT1 (91)
Mitosis CDK11 (p58PITSLRE) (59)
CDK1 (86)
ODC1 (88)
IRES ELEMENTS IN CANCER-RELATED
GENES
Although capped, some cellular mRNAs thay play im-
portant role in many cellular pathways contain IRES ele-
ments within their 5’ UTR that may allow them to be trans-
lated under different physiological or stressful conditions
(e.g., amino acid starvation, apoptosis, growth arrest, heat
shock, mitosis, radiation) when global cap-dependent protein
synthesis is suppressed (46). In contrast, IRES-dependent
translation is completely or partially resistant to this inhi-
bition. At the moment there are around 70 experimentally
verified cellular IRES elements (47) and a large number of
those are found in cancer-related genes (48) (Table 2).
Since IRES-dependent translation relies on different
mechanism and requires several unique protein factors com-
pared with cap-dependent translation it was suggested that
IRES-dependent regulation may escape the control of check
points present in cap-dependent regulation (49). Most can-
cer-related cellular IRESes are differentially regulated, e.g.,
IRES element of the oncogene c-Myc is upregulated fol-
lowing genotoxic stress (50), VEGF IRES shows regulation
by hypoxia (51) and the XIAP IRES element is upregulated
after g-irradiation or anoxia (52). Those condition requires
rapid responses that could be achieved by regulation of RNA
metabolism (e.g., splicing, turnover, translation) more effi-
ciently than by de novo mRNA synthesis.
Oncogenes and Tumor Suppressors
c-Myc is a member of the mammalian transcription fac-
tors of the bHLH-zip family and a potent oncogene. De-
regulated expression of myc genes is frequent in cancers and
ectopic expression is sufficient to induce cell cycle progres-
sion. Translational control of c-Myc was suggested by the
discovery of an mRNA isoform that lacks the 5’ UTR and is
more translationally efficient. It was subsequently discover-
ed that c-Myc 5’ UTR contains a functional IRES element
directing c-Myc translation (53, 54). In 42% of patients with
multiple myeloma there was an acquired single nucleotide
mutation in the c-Myc IRES element resulting in a dramatic
increase in c-Myc translation (55).
Also N-Myc (56), c-Jun (57), and ornithine decarboxy-
lase 1 (ODC1) can be translated by IRES-dependent mecha-
nisms (58). Translation of both c-Myc and ODC1 was shown
to be upregulated during cell cycle progression.
Another cell cycle regulated gene translated through
IRES-dependent manner is protein kinase p58PITSLRE, a
member of cyclin-dependent protein kinases (CDK) (59).
p58PITSLRE is often deleted in neuroblastomas, malignant
melanoma, non-Hodgkin lymphomas, childhood endo-
dermal sinus tumors and its levels correlate with aggressive
tumor growth (60). The inhibitor of CDK CDKN1B
(p27Kip1) is also translated through IRES during cell cycle
(61). CDKN1B plays a central role in the regulation of cell
proliferation and differentiation. The levels of p27Kip1 are
frequently downregulated in cancer cells and often correlate
with poor clinical outcome (62).
The tumor suppressor protein p53 has a key role in
maintaining genomic integrity by controlling cell-cycle pro-
gression and cell survival. Two IRESes have been described
that can mediate the translation of both full-length and
DN-p53 isoforms. The IRES directing the translation of
full-length p53 is in the 5' UTR, whereas the IRES mediat-
ing the translation of DN-p53 extends into the protein-coding
region. The two IRESes show distinct activities depending
on the cell-cycle phase – the IRES for full-length p53 is
active at G2–M transition and that for DN-p53 shows high-
est activity at the G1–S transition (63).
Growth Factors
Fibroblast growth factor-2 (FGF2) promotes epithelial
proliferation and angiogenesis. FGF2 mRNA contains a
long and structured 5' UTR and its translation is initiated
either at primary AUG codon or at one of three upstream
CUG codons. Translation of all four isoforms is IRES-
-driven with the same efficiency (64). Interestingly, many
breast carcinomas that show elevated levels of eIF4E also
exhibit translational deregulation of FGF2 (28).
Although vascular endothelial growth factor A (VEGFA)
is not itself considered an oncogene, it is upregulated in
tumorigenesis and it is important for pathological angio-
genesis in solid tumors (65). Blood-vessel formation is criti-
cal in tumorigenesis and prevention of angiogenesis may
lead to tumor regression. Two hypoxia-responsive IRESes
are involved in VEGFA translational upregulation (51, 66).
Translation of hypoxia-inducible factor-1a (HIF1A), a
major transcriptional activator of hypoxia-inducible genes,
is also mediated by an IRES element (67).
The proto-oncogene c-Sis encodes for the B chain of
platelet-derived growth factor (PDGFB) and its mRNA
possesses an extremely long 5' UTR that inhibits translation
by cap-dependent mechanism (68). On the contrary, an
IRES element that was identified within this 5' UTR very
effectively initiates translation of PDGFB (69). Activity of
IRES is enhanced during cellular differentiation which sug-
gests that IRES-dependent regulation could restrict expres-
sion of PDGFB to the required cell types. PDGFB regulates
mesenchymal cell migration and proliferation, and its aber-
rant expression was implicated in both cancer development
and progression (70).
Human insulin-like growth factor 2 (IGF2) regulates fetal
development and growth, and is connected with various
human cancers, e.g., lung, colon, prostate, and hepatocellular
carcinoma (71). Transcription from IGF2 locus generates four
diverse transcripts that are differentially expresses depending
on the developmental state. Transcripts have different 5' UTR
but share identical coding region, and one of them (leader 2)
can be translated in a cap-independent manner (72).
Proteins Involved in the Regulation
of Apoptosis
Almost all cancer therapies trigger apoptosis, programmed
cell death in target cells. Protein synthesis is mostly halted
during apoptosis as many initiation factors, e.g., eIF4G,
eIF4B, eIF2a and 4EBPs are targeted and cleaved by caspa-
ses thus disabling the protein synthesis machinery (73). Se-
veral genes that are involved in the regulation of apoptosis
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are translated by IRES-dependent mechanism, suggesting
that IRES-directed translation of cellular mRNAs represents
a crucial regulatory point for the survival and proliferation
of cells under transient apoptotic stress (49).
X-linked inhibitor of apoptosis protein (XIAP) is the
most potent intrinsic inhibitor of caspases (74). Like other
inhibitor of apoptosis proteins (IAPs), XIAP inhibits both
the initiator (caspase-9) and effector (caspase-3, caspase-7)
caspases. XIAP mRNA contains an extremely long 5' UTR
containing an IRES element that is translationally active
under cellular stress conditions such as serum starvation
(75), low dose g-irradiation-induced apoptosis (76) or anoxia
(77). IRES-mediated translation of XIAP is upregulated in
response to irradiation and enhances the survival of some
cancer cell lines, suggesting that IRES translation may be
critically involved in cancer progression (52).
BCL2-associated athanogene (BAG1/RAP46) encodes
for a multifunctional protein BAG-1 produced as several
different isoforms with distinct cellular functions including
regulation of cell survival (78), protein refolding (79) and
signal transduction (80). The translation of the most highly
expressed isoform, p36/BAG-1S, is mediated by both cap-
-dependent and IRES-dependent mechanisms (81) of which
the latter is preferentially utilized in cells exposed to heat
shock (82).
Apoptotic protease-activating factor (Apaf-1) is an essen-
tial component of the apoptosome and interacts with the in-
active procaspase-9 facilitating its proteolytic cleavage and
activation (83). The 5' UTR of APAF1 contains an IRES
that is enhanced following the induction of apoptosis by
etoposide suggesting that the IRES-directed translation is
used for ensuring sufficient levels of Apaf-1 protein to pro-
pagate apoptotic signal (77). Caspase-cleaved fragments of
initiation factors eIF4GI and p97/DAP5/NAT1 selectively
activate IRES elements in apoptotic cells (77, 84) which
suggests the existence of a regulatory loop that disables
cap-dependent translation and at the same time enables
IRES-mediated translation of some mRNAs.
Although the number of reports on cellular IRESes is
increasing, their existence still raises skepticism and is often
subject of scientific debates, mainly due to concerns about
the lack of unambiguous experimental verifications (45, 92).
The fact that there are a growing number of cancer-related
genes whose translation regulation can be subjected to cap-
independent initiation makes the quest for discovering and
testing new putative cellular IRESes even more meaningful.
Deciphering their sequence, structure, molecular mecha-
nisms of action and requirements for additional trans-acting
factors will tell us more about how cancer cells can maintain
their growth and sustain their progression in conditions
when general protein synthesis is considerably reduced. Ac-
tual presence of an IRES element within 5' UTR of certain
cancer-related genes could also reveal more about their role
in cancer etiology. A deeper understanding of the mecha-
nisms underlying cap-independent translation regulation in
malignant cells could ultimately lead to novel therapeutic
strategies, that would not affect protein synthesis of normal
cells.
REFERENCES
1. SONENBERG N, HINNEBUSCH A G 2009 Regulation of trans-
lation initiation in eukaryotes: mechanisms and biological targets.
Cell 136: 731–745
2. MATA J, MARGUERAT S, BÄHLER J 2005 Post-transcriptional
control of gene expression: a genome-wide perspective. Trends Bio-
chem Sci 30: 506–514
3. HOLCIK M, SONENBERG N 2005 Translational control in stress
and apoptosis. Nat Rev Mol Cell Biol 6: 318–327
4. LE QUESNE J P, SPRIGGS K A, BUSHELL M, WILLIS A E
2010 Dysregulation of protein synthesis and disease. J Pathol 220:
140–151
5. GRZMIL M, HEMMINGS B A 2012 Translation regulation as a
therapeutic target in cancer. Cancer Res 72: 3891–3900
6. MERRICK W C 2004 Cap-dependent and cap–independent trans-
lation in eukaryotic systems. Gene 332: 1–11
7. JACKSON R J, HELLEN C U, PESTOVA T V 2010 The mecha-
nism of eukaryotic translation initiation and principles of its regu-
lation. Nat Rev Mol Cell Biol 11: 113–127
8. DE BENEDETTI A, GRAFF J R 2004 eIF-4E expression and its
role in malignancies and metastases. Oncogene 23: 3189–3199
9. KOROMILAS A E, LAZARIS-KARATZAS A, SONENBERG N
1992 mRNAs containing extensive secondary structure in their 5’
non-coding region translate efficiently in cells overexpressing initia-
tion factor eIF-4E. EMBO J 11: 4153–4158
10. MAMANE Y, PETROULAKIS E, MARTINEAU Y, SATO T A,
LARSSON O, RAJASEKHAR V K, SONENBERG N 2007 Epige-
netic activation of a subset of mRNAs by eIF4E explains its effects on
cell proliferation. PLoS One 2: e242
11. GRAFF J R, KONICEK B W, CARTER J H, MARCUSSON E G
2008 Targeting the eukaryotic translation initiation factor 4E for
cancer therapy. Cancer Res 68: 631–634
12. LOBO M V, MARTIN M E, PEREZ M I, ALONSO F J, REDON-
DO C, ALVAREZ M I, SALINAS M 2000 Levels, phosphorylation
status and cellular localization of translational factor eIF2 in gastro-
intestinal carcinomas. Histochem J 32: 139–150
13. WANG S, ROSENWALD I B, HUTZLER M J, PIHAN G A,
SAVAS L, CHEN J J, WODA B A 1999 Expression of the eukaryotic
translation initiation factors 4E and 2Alpha in non-Hodgkin’s lym-
phomas. Am J Pathol 155: 247–255
14. LIN L, HOLBRO T, ALONSO G, GEROSA D, BURGER M M
2001 Molecular interaction between human tumor marker protein
p150, the largest subunit of eIF3, and intermediate filament protein
K7. J Cell Biochem 80: 483–490
15. PINCHEIRA R, CHEN Q, ZHANG J T 2001 Identification of a
170-kDa protein over-expressed in lung cancers. Br J Cancer 84:
1520–1527
16. ROTHE M, KO Y, ALBERS P, WERNERT N 2000 Eukaryotic
initiation factor 3 p110 mRNA is overexpressed in testicular semi-
nomas. Am J Pathol 157: 1597–1604
17. MARCHETTI A, BUTTITTA F, PELLEGRINI S, BERTACCA
G, CALLAHAN R 2001 Reduced rxpression of INT-6/eIF3-p48 in
human tumors. Int J Oncol 18: 175–179
18. SHI J, KAHLE A, HERSHEY J W, HONCHAK B M, WARNEKE
J A, LEONG S P, NELSON M A 2006 Decreased expression of
eukaryotic initiation factor 3f deregulates translation and apoptosis
in tumor cells. Oncogene 10: 4923–4936
19. NUPPONEN N N, PORKKA K, KAKKOLA L, TANNER M,
PERSSON K, BORG A, ISOLA J, VISAKORPI T 1999 Ampli-
fication and overexpression of p40 subunit of eukaryotic translation
initiation factor 3 in breast and prostate cancer. Am J Pathol 154:
1777–1783
20. SHUDA M, KONDOH N, TANAKA K, RYO A, WAKATSUKI T,
HADA A, GOSEKI N, IGARI T, HATSUSE K, AIHARA T, HO-
RIUCHI S, SHICHITA M, YAMAMOTO N, YAMAMOTO M
2000 Enhanced expression of translation factor mRNAs in hepato-
cellular carcinoma. Anticancer Res 20: 2489–2494
21. EBERLE J, KRASAGAKIS K, ORFANOS C E 1997 Translation
initiation factor eIF-4A1 mRNA is consistently overexpressed in
human melanoma cells in vitro. Int J Cancer 71: 396–401
22. CREW J P, FUGGLE S, BICKNELL R, CRANSTON D W, DE
BENEDETTI A, HARRIS A L 2000 Eukaryotic initiation factor-4E
in superficial and muscle invasive bladder cancer and its correlation
476 Period biol, Vol 114, No 4, 2012.
P.Ozreti} et al. Cap-independent translation of cancer genes
with vascular endothelial growth factor expression and tumour pro-
gression. Br J Cancer 82: 161–166
23. BERKEL H J, TURBAT-HERRERA E A, SHI R, DE BENEDET-
TI A 2001 Expression of the translation initiation factor eIF4E in the
polyp–cancer sequence in the colon. Cancer Epidemiol Biomarkers
Prev 10: 663–666
24. LI B D, LIU L, DAWSON M, DE BENEDETTI A 1997 Overex-
pression of eukaryotic initiation factor 4E (eIF4E) in breast carcino-
ma. Cancer 79: 2385–2390
25. LI B D, McDONALD J C, NASSAR R, DE BENEDETTI A 1998
Clinical outcome in stage I to III breast carcinoma and eIF4E
overexpression. Ann Surg 227: 756–76l
26. KEREKATTE V, SMILEY K, HU B, SMITH A, GELDER F, DE
BENEDETTI A 1995 The proto-oncogene/translation factor eIF4E:
a survey of its expression in breast carcinomas. Int J Cancer 64: 27–31
27. ROSENWALD I B, CHEN J J, WANG S, SAVAS L, LONDON I
M, PULLMAN J 1999 Upregulation of protein synthesis initiation
factor eIF-4E is an early event during colon carcinogenesis. Oncogene
18: 2507–2517
28. NATHAN C A, CARTER P, LIU L, LI B D, ABREO F, TUDOR A,
ZIMMER S G, DE BENEDETTI A 1997 Elevated Expression of
eIF4E and FGF-2 Isoforms During Vascularization of Breast Carci-
nomas. Oncogene 15: 1087–1094
29. NATHAN C A, FRANKLIN S, ABREO F W, NASSAR R, DE
BENEDETTI A, WILLIAMS J, STUCKER F J 1999 Expression of
eIF4E During Head and Neck Tumorigenesis: Possible Role in
Angiogenesis. Laryngoscope 109: 1253–1258
30. BRASS N, HECKEL D, SAHIN U, PFREUNDSCHUH M,
SYBRECHT G W, MEESE E 1997 Translation initiation factor
eIF-4Gamma is encoded by an amplified gene and induces an
immune response in squamous cell lung carcinoma. Hum Mol
Genet 6: 33–39
31. GUAN X Y, SHAM J S, TANG T C, FANG Y, HUO K K, YANG J
M 2001 Isolation of a novel candidate oncogene within a frequently
amplified region at 3q26 in ovarian cancer. Cancer Res 61: 3806–3809
32. DUA K, WILLIAMS T M, BERETTA L 2001 Translational control
of the proteome: relevance to cancer. Proteomics 1: 1191–1199
33. SPRIGGS K A, BUSHELL M, WILLIS A E 2010 Translational
regulation of gene expression during conditions of cell stress. Mol
Cell 40: 228–237
34. HELLEN C U, SARNOW P 2001 Internal ribosome entry sites in
eukaryotic mRNA molecules. Genes Dev 15: 1593–1612
35. KING H A, COBBOLD L C, WILLIS A E 2010 The role of IRES
trans-acting factors in regulating translation initiation. Biochem Soc
Trans 38: 1581–1586
36. JANG S K, KRAUSSLICH H G, NICKLIN M J, DUKE G M,
PALMENBERG A C, WIMMER E 1988 A segment of the 5’
nontranslated region of encephalomyocarditis virus RNA directs
internal entry of ribosomes during in vitro translation. J Virol 62:
2636–2643
37. PELLETIER J, SONENBERG N 1988 Internal initiation of trans-
lation of eukaryotic mRNA directed by a sequence derived from
poliovirus RNA. Nature 334: 320–325
38. MARTINEZ-SALAS E, RYAN M 2010 Translation and protein
processing. In: Ehrenfeld E, Domingo E, Roos R (ed) The Picorna-
viruses, ASM Press, New York, p 141
39. SARNOW P 1989 Translation of glucose-regulated protein 78/im-
munoglobulin heavy-chain binding protein mRNA is increased in
poliovirus-infected cells at a time when cap-dependent translation of
cellular mRNAs is inhibited. Proc Natl Acad Sci U S A 86: 5795–5799
40. PLANK T D, KIEFT J S 2012 The structures of nonprotein-coding
RNAs that drive internal ribosome entry site function. Wiley Inter-
discip Rev RNA 3: 195–212
41. HALL M N, GABAY J, DEBARBOUILLE M, SCHWARTZ M
1982 A role for mRNA secondary structure in the control of transla-
tion initiation. Nature 295: 616–618
42. LE S Y, MAIZEL J V Jr 1997 A common RNA structural motif
involved in the internal initiation of translation of cellular mRNAs.
Nucleic Acids Res 25: 362–369
43. MARTINEZ-SALAS E, PINEIRO D, FERNANDEZ N 2012 Al-
ternative Mechanisms to Initiate Translation in Eukaryotic mRNAs.
Comp Funct Genomics 2012: 391546
44. VAN EDEN M E, BYRD M P, SHERRILL K W, LLOYD R E 2004
Demonstrating internal ribosome entry sites in eukaryotic mRNAs
using stringent RNA test procedures. RNA 10: 720–730
45. GILBERT W V 2010 Alternative ways to think about cellular inter-
nal ribosome entry. J Biol Chem 285: 29033–29038
46. LOPEZ-LASTRA M, RIVAS A, BARRIA M I 2005 Protein syn-
thesis in eukaryotes: the growing biological relevance of cap-inde-
pendent translation initiation. Biol Res 38: 121–146
47. MOKREJS M, MASEK T, VOPALENSKY V, HLUBUCEK P,
DELBOS P, POSPISEK M 2010 IRESite—a tool for the examina-
tion of viral and cellular internal ribosome entry sites. Nucleic Acids
Res 38: D131–D136 WEB: http://www.iresite.org
48. HOLCIK M 2004 Targeting translation for treatment of cancer—a
novel role for IRES? Curr Cancer Drug Targets 4: 299–311
49. HOLCIK M, SONENBERG N, KORNELUK R G 2000 Internal
ribosome initiation of translation and the control of cell death. Trends
in Gen 16: 469–473
50. SUBKHANKULOVA T, MITCHELL S A, WILLIS A E 2001
Internal ribosome entry segment-mediated initiation of C-myc pro-
tein synthesis following genotoxic stress. Biochem J 359: 183–192
51. STEIN I, ITIN A, EINAT P, SKALITER R, GROSSMAN Z,
KESHET E 1998 Translation of vascular endothelial growth factor
mRNA by internal ribosome entry: implications for translation un-
der hypoxia. Mol Cell Biol 18: 3112–3119
52. HOLCIK M, YEH C, KORNELUK R G, CHOW T 2000 Transla-
tional upregulation of X-linked inhibitor of apoptosis (XIAP) increa-
ses resistance to radiation induced cell death. Oncogene 19: 4174–4177
53. NANBRU C, LAFON I, AUDIGIER S, GENSAC M C, VAGNER
S, HUEZ G, PRATS A C 1997 Alternative translation of the proto-
-oncogene C-myc by an internal ribosome entry site. J Biol Chem
272: 32061–32066
54. STONELEY M, PAULIN F E, LE QUESNE J P, CHAPPELL S A,
WILLIS A E 1998 C-myc 5’ untranslated region contains an internal
ribosome entry segment. Oncogene 16: 423–428
55. CHAPPELL S A, LEQUESNE J P, PAULIN F E, DESCHOOL-
MEESTER M L, STONELEY M, SOUTAR R L, RALSTON S H,
HELFRICH M H, WILLIS A E 2000 A mutation in the C-myc-
IRES leads to enhanced internal ribosome entry in multiple mye-
loma: a novel mechanism of oncogene de-regulation. Oncogene 19:
4437–4440
56. JOPLING C L, WILLIS A E 2001 N-myc Translation is initiated
via an internal ribosome entry segment that displays enhanced acti-
vity in neuronal cells. Oncogene 20: 2664–2670
57. BLAU L, KNIRSH R, BEN-DROR I, OREN S, KUPHAL S, HAU
P, PROESCHOLDT M, BOSSERHOFF A K, VARDIMON L
2012 Aberrant expression of c-Jun in glioblastoma by internal ribo-
some entry site (IRES)-mediated translational activation. Proc Natl
Acad Sci U S A 109: E2875–E2884
58. PYRONNET S, PRADAYROL L, SONENBERG N 2000 A cell
cycle-dependent internal ribosome entry site. Mol Cell 5: 607–616
59. CORNELIS S, BRUYNOOGHE Y, DENECKER G, VAN HUF-
FEL S, TINTON S, BEYAERT R 2000 Identification and charac-
terization of a novel cell cycle-regulated internal ribosome entry site.
Mol Cell 5: 597–605
60. EIPERS P G, BARNOSKI B L, HAN J, CARROLL A J, KIDD V J
1991 Localization of the expressed human p58 protein kinase chro-
mosomal gene to chromosome 1p36 and a highly related sequence to
chromosome 15. Genomics 11: 621–629
61. MISKIMINS W K, WANG G, HAWKINSON M, MISKIMINS R
2001 Control of cyclin–dependent kinase inhibitor p27 expression by
cap-independent translation. Mol Cell Biol 21: 4960–4967
62. LLOYD R V, ERICKSON L A, JIN L, KULIG E, QIAN X, CHE-
VILLE J C, SCHEITHAUER B W 1999 p27kip1: a multifunctional
cyclin-dependent kinase inhibitor with prognostic significance in
human cancers. Am J Pathol 154: 313–323
63. RAY P S, GROVER R, DAS S 2006 Two internal ribosome entry sites
mediate the translation of p53 isoforms. EMBO Rep 7: 404–410
64. BONNAL S, SCHAEFFER C, CREANCIER L, CLAMENS S,
MOINE H, PRATS A C, VAGNER S 2003 A single internal ribo-
some entry site containing a G quartet RNA structure drives fibro-
blast growth factor 2 gene expression at four alternative translation
initiation codons. J Biol Chem 278: 39330–39336
65. PLATE K H, BREIER G, WEICH H A, RISAU W 1992 Vascular
endothelial growth factor is a potential tumour angiogenesis factor
in human gliomas in vivo. Nature 359: 845–848
66. HUEZ I, CREANCIER L, AUDIGIER S, GENSAC M C, PRATS
A C, PRATS H 1998 Two independent internal ribosome entry sites
Period biol, Vol 114, No 4, 2012. 477
Cap-independent translation of cancer genes P.Ozreti} et al.
are involved in translation initiation of vascular endothelial growth
factor mRNA. Mol Cell Biol 18: 6178–6190
67. LANG K J D, KAPPEL A, GOODALL G J 2002 Hypoxia-induci-
ble factor-1alpha mRNA contains an internal ribosome entry site
that allows efficient translation during normoxia and hypoxia. Mol
Biol Cell 13: 1792–1801
68. HORVATH P, SUGANUMA A, INABA M, PAN Y B, GUPTA K C
1995 Multiple elements in the 5’ untranslated region down-regulate
c-sis messenger RNA Translation. Cell Growth Differ 6: 1103–1110
69. BERNSTEIN J, SELLA O, LE S Y, ELROY-STEIN O 1997
PDGF2/c-sis mRNA leader contains a differentiation-linked inter-
nal ribosomal entry site (D-IRES). J Biol, Chem 272: 9356–9362
70. KIM H R, YU J, USTACH C 2003 Platelet-derived growth factor
signaling and human cancer. J Biochem Mol Biol 36: 49–59
71. NIELSEN F C 1992 The Molecular and cellular biology of Insu-
lin-Like Growth Factor II. Prog Growth Factor Res 4: 257–290
72. PEDERSEN S K, CHRISTIANSEN J, HANSEN T O, LARSEN
M R, NIELSEN F C 2002 Human Insulin-Like Growth Factor II
Leader 2 mediates internal initiation of translation. Biochem J 363:
37–44
73. MORLEY S J 2001 The Regulation of eIF4F During Cell Growth
and Cell Death. Prog Mol Subcell Biol 27: 1–37
74. HOLCIK M, KORNELUK R G 2001 XIAP, the Guardian Angel.
Nat Rev Mol Cell Biol 2: 550–556
75. HOLICIK M, LEFEBVRE C A, YEH C, CHOW T, KORNELUK
R G 1999 A new internal-ribosome-entry-site motif potentiates XIAP-
-mediated cytoprotection. Nature Cell Biology 1: 190–192
76. HOLCIK M, YEH C, KORNELUK R G, CHOW T 2000 Trans-
lational upregulation of X-Linked Inhibitor of Apoptosis (XIAP)
increases resistance to radiation induced cell death. Oncogene 19:
4174–4177
77. NEVINS T A, HARDER Z M, KORNELUK R G, HOLCIK M
2003 Distinct regulation of internal ribosome entry site-mediated
translation following cellular stress is mediated by apoptotic frag-
ments of eIF4G translation initiation factor family members eIF4GI
and p97/DAP5/NAT1. J Biol Chem 278: 3572–3579
78. TAKAYAMA S, KRAJEWSKI S, KRAJEWSKA M, KITADA S,
ZAPATA J M, KOCHEL K, KNEE D, SCUDIERO D, TUDOR
G, MILLER G J, MIYASHITA T, YAMADA M, REED J C 1998
Expression and location of Hsp70/Hsc-Binding anti-apoptotic pro-
tein BAG-1 and its variants in normal tissues and tumor cell lines.
Cancer Res 58: 3116–3131
79. BIMSTON D, SONG J, WINCHESTER D, TAKAYAMA S, REED
J C, MORIMOTO R I 1998 BAG-1, a negative regulator of Hsp70
chaperone activity, uncouples nucleotide hydrolysis from substrate
release. EMBO J 17: 6871–6878
80. WANG H G, TAKAYAMA S, RAPP U R, REED J C 1996 Bcl-2
interacting protein, BAG-1, binds to and activates the kinase Raf–1.
Proc Natl Acad Sci U S A 93: 7063–7068
81. COLDWELL M J, DESCHOOLMEESTER M L, FRASER G A,
PICKERING B M, PACKHAM G, WILLIS A E 2001 The p36
isoform of BAG-1 is translated by internal ribosome entry following
heat shock. Oncogene 20: 4095–4100
82. COLDWELL M J, DESCHOOLMEESTER M L, FRASER G A,
PICKERING B M, PACKHAM G, WILLIS A E 2001 The p36
isoform of BAG-1 is translated by internal ribosome entry following
heat shock. Oncogene 20: 4095–4100
83. ADAMS J M, CORY S 2002 Apoptosomes: engines for caspase
activation. Curr Opin Cell Biol 14: 715–720
84. Henis-KORENBLIT S, SHANI G, SINES T, MARASH L, SHO-
HAT G, KIMCHI A 2002 The caspase-cleaved DAP5 protein sup-
ports internal ribosome entry site-mediated translation of death
proteins. Proc Natl Acad Sci U S A 99: 5400–5405.
85. GRABER T E, BAIRD S D, KAO P N, MATHEWS M B, HOL-
CIK M 2010 NF45 functions as an IRES transacting factor that is
required for translation of cIAP1 during the unfolded protein res-
ponse. Cell Death and Differentiation 17: 719–729
86. MARASH L, LIBERMAN N, HENIS-KORENBLIT S, SIVAN G,
REEM E, ELROY-STEIN O, KIMCHI A 2008 DAP5 promotes
cap-independent translation of Bcl-2 and CDK1 to facilitate cell
survival during mitosis. Mol Cell 30: 447–459
87. HOOVER D S, WINGETT D G, ZHANG J, REEVES R, MAG-
NUSON N S 1997 Pim-1 protein expression is regulated by its
5’-untranslated region and translation initiation factor elF-4E. Cell
Growth Differ 8: 1371–1380
88. PYRONNET S, PRADAYROL L, SONENBERG N 2005 Alter-
native splicing facilitates internal ribosome entry on the ornithine
decarboxylase mRNA. Cell Mol Life Sci 62: 1267–1274
89. HEPPNER, GOSS K, TRZEPACZ C, TUOHY T M, GRODEN J
2002 Attenuated APC alleles produce functional protein from inter-
nal translation initiation. Proc Natl Acad Sci U S A 99: 8161–8166
90. JIMENEZ J, JANG G M, SEMLER B L, WATERMAN M L 2005
An internal ribosome entry site mediates translation of lymphoid
enhancer factor-1. RNA 11: 1385–1399
91. FOX J T, STOVER P J 2009 Mechanism of the internal ribosome
entry site-mediated translation of serine hydroxymethyltransferase
1. J Biol Chem 284: 31085–31096
92. KOZAK M 2005 A second look at cellular mRNA sequences said
to function as internal ribosome entry sites. Nucleic Acids Res 33:
6593–6602
478 Period biol, Vol 114, No 4, 2012.
P.Ozreti} et al. Cap-independent translation of cancer genes
